Lapatinib is classified as a signal transduction inhibitor - tyrosine kinase inhibitor, inhibitor of EGFR and HER2. Lapatinib is marketed as Tykerb and is used in the treatment of metastatic breast cancer that is HER-2 positive. The drug may also be used in combination with other chemotherapy drugs or for the treatment of other cancers.

Related categories 1

RxList: Tykerb (Lapatinib)
Provides medication description and drug information including side effects, interactions, and patient labeling.
Last update:
April 20, 2008 at 0:33:02 UTC
Health
Home
News
Recreation
Reference
Regional
Science
Shopping
Society
Sports
All Languages
Arts
Business
Computers
Games